{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-085399","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.600073+00:00","generated_at":"2026-05-15T22:47:18.282391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tyra Biosciences reports FY2025 net loss of $119.9M; cash $256M, outlines dabogratinib 3x3 strategy","bullets":["Q4 2025 net loss $33.8M vs $25.6M; FY net loss $119.9M vs $86.5M; R&D spend rose to $102.9M.","Cash, equivalents and marketable securities $256.0M at Dec 31, 2025; runway through at least 2027.","Launched 'dabogratinib 3x3' strategy: three pivotal-ready studies in LG-UTUC, IR NMIBC, and ACH.","SURF302 (IR NMIBC) initial 3-month CR data expected by end 1H 2026; BEACH301 (ACH) interim results 2H 2026.","Appointed Bhavesh Ashar as COO and Heather Faulds as Chief Regulatory Officer in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-085399","json":"https://secwatch.observer/filing/0001193125-26-085399.json","markdown":"https://secwatch.observer/filing/0001193125-26-085399.md","text":"https://secwatch.observer/filing/0001193125-26-085399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/0001193125-26-085399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/tyra-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:47:18.282391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}